BioCentury
ARTICLE | Company News

Teva gets Agilect approvable letter

July 6, 2004 7:00 AM UTC

TEVA received an FDA approvable letter for Agilect rasagiline to treat Parkinson's disease (PD). The irreversible selective inhibitor of the monoamine oxide type B enzyme ( MAO-B) is under review in E...